Citations

Mayo Clinic

Showing 10 of 108599 citations.

Prevalence of Developmental Venous Anomalies Increases With Age
Brinjikji, Waleed , Masri, Ali El Rida El , Wald, John T. , El-Rida El-Masri, Ali, Lanzino, Giuseppe

Stroke | May 23, 2017 | Volume: 48 | Issue: 7 | Pages: 1997-1999

10.1161/strokeaha.116.016145 | PMID 28536179 Get It

Background and Purpose— To test the hypothesis that developmental venous anomalies (DVAs) may develop in the postnatal period, we studied the age-related prevalence of DVAs on contrast-enhanced magnetic resonance imaging. Methods— Reports from a consecutive series of head magnetic resonance images with intravenous contrast performed over a 2-year period at our institution were reviewed. Studies reporting the presence of a DVA were retrieved and reviewed by a neuroradiologist. Patients were divided into 4 age groups: (1) <1 year old (neonates/infants), (2) 1 to 5 years old (toddlers and preschoolers), (3) 6 to 17 years old (grade schoolers), and (4) ≥18 years old (adults), and DVA prevalence by age group was studied. Results— A total of 18 073 individuals were included. DVA prevalence in the neonate/infant age group was 1.5% (5/335) compared with 7.1% (51/714) in the toddler/preschool age group. In both the grade-school age group and adult age group, DVA prevalence was 9.6% (150/1557 and 1483/15 467, respectively). Neonates/infants were significantly less likely to have DVAs than other age groups ( P <0.001). Conclusions— We found a very low prevalence of DVAs on contrast-enhanced magnetic resonance imaging in patients <1 year old which was significantly lower than other age groups. These findings suggest that postnatal changes in venous architecture and drainage patterns may contribute to the development of DVAs.
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes
Xochelli, Aliki , Kavakiotis, Ioannis , Agathangelidis, Andreas , Sutton, Lesley-Ann, Minga, Eva, Ntoufa, Stavroula , Tausch, Eugen , Yan, Xiao‐Jie , Plevová, Karla , Boudjogra, Myriam, Rossi, Davide , Davis, Zadie , Navarro, Alba , Sandberg, Yorick , Vojdeman, Fie Juhl , Scarfò, Lydia , Stavroyianni, Niki, Sudarikov, Andrey , Τζένου, Τατιάνα , Karan-Djurašević, Teodora , Catherwood, Mark , Kienle, Dirk, Chatzouli, Maria, Facco, Monica , Bahlo, Jasmin, Pott, Christiane , Pedersen, Lone Bredo , Mansouri, Larry, Smedby, Karin E. , Chu, Charles C. , Giudicelli, Véronique , Lefranc, Marie‐Paule , Juliusson, Gunnar , Anagnostopoulos, Αchilles , Antić, Darko , Trentin, Livio , Montillo, Marco , Niemann, Carsten Utoft , Pospı́šilová, Šárka , Hallek, Michael , Maglaveras, Nikos, Oscier, David , Gaïdano, Gianluca , Jelinek, Diane F., Chouvarda, Ioanna , Darzentas, Nikos , Belessi, Chrysoula, Davi, Frédéric , Hadzidimitriou, Anastasia , Rosenquist, Richard , Ghia, Paolo , Σταματόπουλος, Κώστας , Maglaveras, Nicos , Baliakas, Panagiotis , Sutton, Lesley‐Ann, Shanafelt, Tait D. , Veronese, Silvio , Panagiotidis, Panagiotis T. , Vlahavas, Ioannis P. , Döhner, Hartmut , Langerak, Anton W. , Campo, Elı́as , Chiorazzi, Nicholas , Stilgenbauer, Stephan , Gaidano, Gianluca , Ghia, Paolo , Rosenquist, Richard

Clinical Cancer Research | May 23, 2017 | Volume: 23 | Issue: 17 | Pages: 5292-5301

10.1158/1078-0432.ccr-16-3100 | PMID 28536306 Get It

Abstract Purpose: We sought to investigate whether B cell receptor immunoglobulin (BcR IG) stereotypy is associated with particular clinicobiological features among chronic lymphocytic leukemia (CLL) patients expressing mutated BcR IG (M-CLL) encoded by the IGHV4-34 gene, and also ascertain whether these associations could refine prognostication. Experimental Design: In a series of 19,907 CLL cases with available immunogenetic information, we identified 339 IGHV4-34–expressing cases assigned to one of the four largest stereotyped M-CLL subsets, namely subsets #4, #16, #29 and #201, and investigated in detail their clinicobiological characteristics and disease outcomes. Results: We identified shared and subset-specific patterns of somatic hypermutation (SHM) among patients assigned to these subsets. The greatest similarity was observed between subsets #4 and #16, both including IgG-switched cases (IgG-CLL). In contrast, the least similarity was detected between subsets #16 and #201, the latter concerning IgM/D-expressing CLL. Significant differences between subsets also involved disease stage at diagnosis and the presence of specific genomic aberrations. IgG subsets #4 and #16 emerged as particularly indolent with a significantly (P &lt; 0.05) longer time-to-first-treatment (TTFT; median TTFT: not yet reached) compared with the IgM/D subsets #29 and #201 (median TTFT: 11 and 12 years, respectively). Conclusions: Our findings support the notion that BcR IG stereotypy further refines prognostication in CLL, superseding the immunogenetic distinction based solely on SHM load. In addition, the observed distinct genetic aberration landscapes and clinical heterogeneity suggest that not all M-CLL cases are equal, prompting further research into the underlying biological background with the ultimate aim of tailored patient management. Clin Cancer Res; 23(17); 5292–301. ©2017 AACR.
Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals
Vassilaki, Maria , Christianson, Teresa J., Mielke, Michelle M. , Geda, Yonas E. , Kremers, Walter K. , Petersen, Ronald C. , Lowe, Val J. , Jack, Clifford R. , Roberts, Rosebud O., Machulda, Mary M. , Knopman, David S. , Jack, Clifford R , Mielke, Michelle M , Geda, Yonas E , Kremers, Walter K

Annals of Neurology | May 23, 2017 | Volume: 81 | Issue: 6 | Pages: 871-882

10.1002/ana.24960 | PMID 28543731 Get It

Objective There is a need for inexpensive noninvasive tests to identify older healthy persons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials. Our objective was to examine whether abnormalities in neuroimaging measures of amyloid and neurodegeneration are correlated with odor identification (OI) in the population‐based Mayo Clinic Study of Aging. Methods Cognitively normal (CN) participants had olfactory function assessed using the Brief Smell Identification Test (B‐SIT), underwent magnetic resonance imaging (n = 829) to assess a composite AD signature cortical thickness and hippocampal volume (HVa), and underwent 11 C‐Pittsburgh compound B (n = 306) and 18 fluorodeoxyglucose (n = 305) positron emission tomography scanning to assess amyloid accumulation and brain hypometabolism, respectively. The association of neuroimaging biomarkers with OI was examined using multinomial logistic regression and simple linear regression models adjusted for potential confounders. Results Among 829 CN participants (mean age = 79.2 years; 51.5% men), 248 (29.9%) were normosmic and 78 (9.4%) had anosmia (B‐SIT score < 6). Abnormal AD signature cortical thickness and reduced HVa were associated with decreased OI as a continuous measure (slope = −0.43, 95% confidence interval [CI] = −0.76 to −0.09, p = 0.01 and slope = −0.72, 95% CI = −1.15 to −0.28, p < 0.01, respectively). Reduced HVa, decreased AD signature cortical thickness, and increased amyloid accumulation were significantly associated with increased odds of anosmia. Interpretation Our findings suggest that OI may be a noninvasive, inexpensive marker for risk stratification, for identifying participants at the preclinical stage of AD who may be at risk for cognitive impairment and eligible for inclusion in AD prevention clinical trials. These cross‐sectional findings remain to be validated prospectively. Ann Neurol 2017;81:871–882
Predictors of incident proteinuria among patients with SLE
Barr, Erik , Magder, Laurence S. , Petri, Michelle , Duarte‐García, Alí

Lupus Science & Medicine | May 23, 2017 | Volume: 4 | Issue: 1 | Pages: e000200

10.1136/lupus-2016-000200 | PMID 29177060 Get It

Objective To identify fixed and time-varying predictors of incident proteinuria. Methods This analysis was based on patients who did not have a history of diabetes and who did not have a prior episode of renal involvement. We defined an incident case of proteinuria as two or more measures of urine protein to creatinine ratio (or 24-hour protein measure) greater than 0.5 in two visits separated by more than 30 days and less than 180 days. We estimated rates of incident proteinuria in subgroups of patients with lupus defined by time-invariant and time-varying predictors. Results Among 895 patients included in the analysis, 840 (94%) were female, and 518 (58%) were Caucasian, 304 (34%) African-American, with mean age of 42 years at the start of follow-up. We observed 57 incident cases of proteinuria over a span of 4669 person-years of cohort follow-up. The overall rate of incident proteinuria was 12.2 per 1000 person-years. The rate was significantly lower among those of older age, and higher among those who were not Caucasian. In those with a very low C3 measure in a previous cohort visit, the rate was increased by a factor of 16.1 and in those with a very low C4 by 16.3. The rate among those prescribed hydroxychloroquine or ACE inhibitors/ARB was similar to those not on them. Conclusions Older patients with SLE are at low risk for developing proteinuria. There was not strong evidence that hydroxychloroquine or angiotensin-converting-enzyme (ACE) inhibitor reduced the risk of proteinuria. The highest rates of incident proteinuria were among those with recent low complement.
Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation
Black‐Maier, Eric , Kim, Sunghee , Steinberg, Benjamin A. , Fonarow, Gregg C. , Kowey, Peter R. , Ansell, Jack , Mahaffey, Kenneth W. , Go, Alan S. , Piccini, Jonathan P. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Freeman, James V. , Gersh, Bernard J. , Naccarelli, Gerald V. , Hylek, Elaine M. , Peterson, Eric D. , Investigators, for the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT‐AF), Steinberg, Benjamin A

Clinical Cardiology | May 23, 2017 | Volume: 40 | Issue: 9 | Pages: 746-751

10.1002/clc.22726 | PMID 28543401 Get It

BackgroundOral anticoagulation (OAC) therapy is associated with increased periprocedural risks after cardiac implantable electronic device (CIED) implantation. Patterns of anticoagulation management involving non–vitamin K antagonist oral anticoagulants (NOACs) have not been characterized.HypothesisAnticoagulation strategies and outcomes differ by anticoagulant type in patients undergoing CIED implantation.MethodsUsing the nationwide Outcomes Registry for Better Informed Treatment of Atrial Fibrillation, we assessed how atrial fibrillation (AF) patients undergoing CIED implantation were cared for and their subsequent outcomes. Outcomes were compared by oral anticoagulant therapy (none, warfarin, or NOAC) as well as by anticoagulation interruption status.ResultsAmong 9129 AF patients, 416 (5%) underwent CIED implantation during a median follow‐up of 30 months (interquartile range, 24–36). Of these, 60 (14%) had implantation on a NOAC. Relative to warfarin therapy, those on a NOAC were younger (70.5 years [range, 65–77.5 years] vs 77 years [range, 70–82 years]), had less valvular heart disease (15.0% vs 31.3%), higher creatinine clearance (67.3 [range, 59.7–99.0] vs 65.8 [range, 50.0–91.6]), were more likely to have persistent AF (26.7% vs 22.9%), and use concomitant aspirin (51.7% vs 35.2%). OAC therapy was commonly interrupted for CIED in 64% (n = 183 of 284) of warfarin patients and 65% (n = 39 of 60) of NOAC patients. Many interrupted patients received intravenous bridging anticoagulation: 33/183 (18%) interrupted warfarin and 4/39 (10%) interrupted NOAC patients. Thirty‐day periprocedure bleeding and stroke adverse events were infrequent.ConclusionsManagement of anticoagulation among AF patients undergoing CIED implantation is highly variable, with OAC being interrupted in more than half of both warfarin‐ and NOAC‐treated patients. Bleeding and stroke events were infrequent in both warfarin and NOAC‐treated patients.
Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management
Heyes, Richard , Northfelt, Donald W. , Lott, David G.

Otolaryngology–Head and Neck Surgery | May 23, 2017 | Volume: 157 | Issue: 5 | Pages: 750-759

10.1177/0194599817707208 | PMID 28535360 Get It

ObjectivePosttransplant lymphoproliferative disorder (PTLD) is a unifying term for a spectrum of lymphoid expansion entities brought about by immunosuppression and is strongly associated with Epstein‐Barr virus (EBV). Otolaryngological findings tend to present early in the clinical course; therefore, disease awareness among otolaryngologists is of utmost importance. This review synthesizes the body of literature pertaining to PTLD involving the head and neck, summarizes contemporary management, and highlights areas for future research.Data SourcesPubMed/Medline.Review MethodsPrimary literature search of the Medline database was performed for all titles published in the past 10 years pertaining to PTLD. The database search included PTLD combined with a collection of otolaryngological MeSH terms. Full manuscripts were reviewed based on relevance of their title and abstract. Selection into this review was according to clinical and scientific relevance.ConclusionAdenotonsillar focus is common in children in whom adenotonsillectomy may be diagnostic and prevents potentially morbid airway obstruction. Sinonasal PTLD may mimic fungal infection. Laryngotracheal involvement predominately presents in children with symptoms of airway obstruction. PTLD limited to the esophagus is rare. Oral PTLD is rare and phenotypically varied. Cutaneous presentation of PTLD is infrequent, yet one‐third of cases affects the head and neck. PTLD may present as cervical lymphadenopathy.Implications for PracticePTLD consideration is vital when evaluating posttransplant patients. Children and EBV‐seronegative patients should receive otolaryngological follow‐up after transplant. PTLD treatment is multidisciplinary and typically led by lymphoma specialists. Formal partnerships between otolaryngologists and transplant centers may improve patient care and research quality.
Aura and Other Neurologic Dysfunction in or with Migraine
Cutrer, F. Michael , Cutrer, Fred Michael, Kissoon, Narayan

Headache: The Journal of Head and Face Pain | May 23, 2017 | Volume: 57 | Issue: 7 | Pages: 1179-1194

10.1111/head.13101 | PMID 28542895 Get It

Premise Migraine can present with a wide range of neurological symptoms. Problem Based on currently available data, the symptoms of typical migraine aura are most likely related to cortical spreading depression (CSD), and evidence supports that CSD can lead to trigeminovascular activation resulting in the headache phase of migraine. Potential Solution An alternative diagnosis to migraine aura should be considered if migrainous headaches present with transient neurological symptoms that have features inconsistent with aura.
Decompressive Hemicraniectomy in the Setting of Poststroke Cerebral Edema: A Case for Early Intervention
Aoun, Rami James N. , Gupta, Aman , Welz, Matthew E., Bendok, Bernard R.

Neurosurgery | May 23, 2017 | Volume: 81 | Issue: 1 | Pages: N11-N13

10.1093/neuros/nyx252 | PMID 28873989 Get It

Correction for Evans et al., “Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics To Identify Susceptibility and Resistance to Carbapenems against Acinetobacter spp. in PRIMERS III”
Hujer, Andrea M. , Jiang, Hongyu , Hill, Carol , Hujer, Kristine M., Mediavilla, José R. , Tran, Thuy Tien T., Higgins, Paul G. , Kreiswirth, Barry N. , Patel, Robin , Chen, Liang , Sampath, Rangarajan , Marzan, Christine, Fowler, Vance G. , Chambers, Henry F. , Evans, Scott , Manca, Claudia , Domitrovic, Tatiana , Seifert, Harald , Kreiswirth, Barry N , Jacobs, Michael R. , Chen, Liang , Hall, Thomas A. , Fowler, Vance G. , Bonomo, Robert A. , Patel, Robin , Evans, Scott R

Journal of Clinical Microbiology | May 23, 2017 | Volume: 55 | Issue: 6 | Pages: 1970-1970

10.1128/jcm.00525-17 | PMID 28536161 Get It

Analyses of thrombi in acute ischemic stroke: A consensus statement on current knowledge and future directions
Andersson, Tommy , Baxter, Blaise, Brouwer, Patrick A. , Brinjikji, Waleed , Costalat, Vincent , Dávalos, Antoni , Demchuk, Andrew M. , Dippel, Diederik W.J. , Fischer, Urs , Gilvarry, Michael , Gounis, Matthew J. , Gralla, Jan , Jansen, Olav , Kallmes, David F. , Khatri, Pooja , López‐Cancio, Elena , Majoie, Charles B.L.M. , Marquering, Henk A. , Narata, Ana Paula , Siddiqui, Adnan H. , Szikora, István , Vale, David, Hacke, Werner , Liebeskind, David S. , Kallmes, David, De Meyer, Simon F , Bendszus, Martin , Campbell, Bruce , Fiehler, Jens , Jovin, Tudor G. , Lees, Kennedy R. , Nogueira, Raul G. , Ringleb, Peter Arthur , Kummer, Rüdiger von , Yoo, Albert J. , Liebeskind, David S. , Siddiqui, Adnan H , Szikora, Istvan , Andersson, Tommy , Demchuk, Andrew M , Brouwer, Patrick , Fischer, Urs , Marquering, Henk A , Majoie, Charles B L M , Khatri, Pooja

International Journal of Stroke | May 23, 2017 | Volume: 12 | Issue: 6 | Pages: 606-614

10.1177/1747493017709671 | PMID 28534706 Get It

Limited data exist on clot composition and detailed characteristics of arterial thrombi associated with large vessel occlusion in acute ischemic stroke. Advances in endovascular thrombectomy and related imaging modalities have created a unique opportunity to analyze thrombi removed from cerebral arteries. Insights into thrombus composition, etiology, physical properties and neurovascular interactions may lead to future advancements in acute ischemic stroke treatment and improved clinical outcomes. Advances in imaging techniques may enhance clot characterization and inform therapeutic decision-making prior to treatment and reveal stroke etiology to guide secondary prevention. Current imaging techniques can provide some information about thrombi, but there remains much to evaluate about relationships that may exist among thrombus composition, occlusion characteristics and treatment outcomes. Improved pathophysiological characterization of clot types, their properties and how these properties change over time, together with clinical correlates from ongoing studies, may facilitate revascularization with thrombolysis and thrombectomy. Interdisciplinary approaches covering clinical, engineering and scientific aspects of thrombus research will be key to advancing the understanding of thrombi and improving acute ischemic stroke therapy. This consensus statement integrates recent research on clots and thrombi retrieved from cerebral arteries and provides a rationale for further analyses, including current opportunities and limitations.